SP1 and urinary bladder carcinoma: The activity of the hTR promoter is controlled by NF-Y, Sp1 and Sp3 in bladder cancer cells in vitro and we have recently shown that an Sp1 site mutation in the hTR promoter detected in a blood sample taken from a paroxysmal nocturnal haemoglobinuria (PNH) patient can alter core promoter activity in vitro, raising the possibility that mutation might affect hTR gene transcription in hematopoietic cells in vivo [12-14].